Impact of regurgitation on health-related quality of life in gastro-oesophageal re flux disease before and after short-term potent acid suppression therapy

Peter J. Kahrilas, Andreas Jonsson, Hans Denison, Börje Wernersson, Nesta Hughes, Colin Howden

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objective: Limited data exist on the impact of regurgitation on health-related quality of life (HRQOL) in gastro-oesophageal reflux disease (GORD). We assessed the relationship between regurgitation frequency and HRQOL before and after acid suppression therapy in GORD. Method: We used data from two randomised trials of AZD0865 25-75 mg/day versus esomeprazole 20 or 40 mg/day in non-erosive reflux disease (NERD) (n=1415) or reflux oesophagitis (RO) (n=1460). The Reflux Disease Questionnaire was used to select patients with frequent and intense heartburn for inclusion and to assess treatment response. The Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire was used to assess HRQOL. Results: At baseline, 93% of patients in both the NERD and RO groups experienced regurgitation. Mean QOLRAD scores were similar for NERD and RO at baseline and at week 4 and disclosed decremental HRQOL with increasing frequency of regurgitation; a clinically relevant difference of >0.5 in mean QOLRAD scores was seen with regurgitation ≥4 days/week versus <4 days/week. The prevalence of frequent, persistent regurgitation (≥4 days/week) at week 4 among heartburn responders (≤1 day/week of mild heartburn) was 28% in NERD and 23% in RO. QOLRAD scores were higher among heartburn responders. There was a similar pattern of impact related to regurgitation frequency in heartburn responders compared with the group as a whole. Conclusions: Frequent regurgitation was associated with a clinically relevant, incremental decline in HRQOL beyond that associated with heartburn before and after potent acid suppression in both NERD and RO. Clinical trial numbers: NCT00206284 and NCT00206245.

Original languageEnglish (US)
Pages (from-to)720-726
Number of pages7
JournalGut
Volume63
Issue number5
DOIs
StatePublished - May 1 2014
Externally publishedYes

Fingerprint

Heartburn
Quality of Life
Peptic Esophagitis
Acids
Dyspepsia
Esophageal Diseases
Therapeutics
Gastroesophageal Reflux
Esomeprazole
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

Impact of regurgitation on health-related quality of life in gastro-oesophageal re flux disease before and after short-term potent acid suppression therapy. / Kahrilas, Peter J.; Jonsson, Andreas; Denison, Hans; Wernersson, Börje; Hughes, Nesta; Howden, Colin.

In: Gut, Vol. 63, No. 5, 01.05.2014, p. 720-726.

Research output: Contribution to journalArticle

Kahrilas, Peter J. ; Jonsson, Andreas ; Denison, Hans ; Wernersson, Börje ; Hughes, Nesta ; Howden, Colin. / Impact of regurgitation on health-related quality of life in gastro-oesophageal re flux disease before and after short-term potent acid suppression therapy. In: Gut. 2014 ; Vol. 63, No. 5. pp. 720-726.
@article{251a81215ebb4833950770e043516e00,
title = "Impact of regurgitation on health-related quality of life in gastro-oesophageal re flux disease before and after short-term potent acid suppression therapy",
abstract = "Objective: Limited data exist on the impact of regurgitation on health-related quality of life (HRQOL) in gastro-oesophageal reflux disease (GORD). We assessed the relationship between regurgitation frequency and HRQOL before and after acid suppression therapy in GORD. Method: We used data from two randomised trials of AZD0865 25-75 mg/day versus esomeprazole 20 or 40 mg/day in non-erosive reflux disease (NERD) (n=1415) or reflux oesophagitis (RO) (n=1460). The Reflux Disease Questionnaire was used to select patients with frequent and intense heartburn for inclusion and to assess treatment response. The Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire was used to assess HRQOL. Results: At baseline, 93{\%} of patients in both the NERD and RO groups experienced regurgitation. Mean QOLRAD scores were similar for NERD and RO at baseline and at week 4 and disclosed decremental HRQOL with increasing frequency of regurgitation; a clinically relevant difference of >0.5 in mean QOLRAD scores was seen with regurgitation ≥4 days/week versus <4 days/week. The prevalence of frequent, persistent regurgitation (≥4 days/week) at week 4 among heartburn responders (≤1 day/week of mild heartburn) was 28{\%} in NERD and 23{\%} in RO. QOLRAD scores were higher among heartburn responders. There was a similar pattern of impact related to regurgitation frequency in heartburn responders compared with the group as a whole. Conclusions: Frequent regurgitation was associated with a clinically relevant, incremental decline in HRQOL beyond that associated with heartburn before and after potent acid suppression in both NERD and RO. Clinical trial numbers: NCT00206284 and NCT00206245.",
author = "Kahrilas, {Peter J.} and Andreas Jonsson and Hans Denison and B{\"o}rje Wernersson and Nesta Hughes and Colin Howden",
year = "2014",
month = "5",
day = "1",
doi = "10.1136/gutjnl-2013-304883",
language = "English (US)",
volume = "63",
pages = "720--726",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",
number = "5",

}

TY - JOUR

T1 - Impact of regurgitation on health-related quality of life in gastro-oesophageal re flux disease before and after short-term potent acid suppression therapy

AU - Kahrilas, Peter J.

AU - Jonsson, Andreas

AU - Denison, Hans

AU - Wernersson, Börje

AU - Hughes, Nesta

AU - Howden, Colin

PY - 2014/5/1

Y1 - 2014/5/1

N2 - Objective: Limited data exist on the impact of regurgitation on health-related quality of life (HRQOL) in gastro-oesophageal reflux disease (GORD). We assessed the relationship between regurgitation frequency and HRQOL before and after acid suppression therapy in GORD. Method: We used data from two randomised trials of AZD0865 25-75 mg/day versus esomeprazole 20 or 40 mg/day in non-erosive reflux disease (NERD) (n=1415) or reflux oesophagitis (RO) (n=1460). The Reflux Disease Questionnaire was used to select patients with frequent and intense heartburn for inclusion and to assess treatment response. The Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire was used to assess HRQOL. Results: At baseline, 93% of patients in both the NERD and RO groups experienced regurgitation. Mean QOLRAD scores were similar for NERD and RO at baseline and at week 4 and disclosed decremental HRQOL with increasing frequency of regurgitation; a clinically relevant difference of >0.5 in mean QOLRAD scores was seen with regurgitation ≥4 days/week versus <4 days/week. The prevalence of frequent, persistent regurgitation (≥4 days/week) at week 4 among heartburn responders (≤1 day/week of mild heartburn) was 28% in NERD and 23% in RO. QOLRAD scores were higher among heartburn responders. There was a similar pattern of impact related to regurgitation frequency in heartburn responders compared with the group as a whole. Conclusions: Frequent regurgitation was associated with a clinically relevant, incremental decline in HRQOL beyond that associated with heartburn before and after potent acid suppression in both NERD and RO. Clinical trial numbers: NCT00206284 and NCT00206245.

AB - Objective: Limited data exist on the impact of regurgitation on health-related quality of life (HRQOL) in gastro-oesophageal reflux disease (GORD). We assessed the relationship between regurgitation frequency and HRQOL before and after acid suppression therapy in GORD. Method: We used data from two randomised trials of AZD0865 25-75 mg/day versus esomeprazole 20 or 40 mg/day in non-erosive reflux disease (NERD) (n=1415) or reflux oesophagitis (RO) (n=1460). The Reflux Disease Questionnaire was used to select patients with frequent and intense heartburn for inclusion and to assess treatment response. The Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire was used to assess HRQOL. Results: At baseline, 93% of patients in both the NERD and RO groups experienced regurgitation. Mean QOLRAD scores were similar for NERD and RO at baseline and at week 4 and disclosed decremental HRQOL with increasing frequency of regurgitation; a clinically relevant difference of >0.5 in mean QOLRAD scores was seen with regurgitation ≥4 days/week versus <4 days/week. The prevalence of frequent, persistent regurgitation (≥4 days/week) at week 4 among heartburn responders (≤1 day/week of mild heartburn) was 28% in NERD and 23% in RO. QOLRAD scores were higher among heartburn responders. There was a similar pattern of impact related to regurgitation frequency in heartburn responders compared with the group as a whole. Conclusions: Frequent regurgitation was associated with a clinically relevant, incremental decline in HRQOL beyond that associated with heartburn before and after potent acid suppression in both NERD and RO. Clinical trial numbers: NCT00206284 and NCT00206245.

UR - http://www.scopus.com/inward/record.url?scp=84897949891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897949891&partnerID=8YFLogxK

U2 - 10.1136/gutjnl-2013-304883

DO - 10.1136/gutjnl-2013-304883

M3 - Article

C2 - 23831734

AN - SCOPUS:84897949891

VL - 63

SP - 720

EP - 726

JO - Gut

JF - Gut

SN - 0017-5749

IS - 5

ER -